Fisher & Paykel Remains Macquarie's Top Pick Stock
Fisher & Paykel Remains Macquarie's Top Pick Stock
Macquarie analysts maintain that Fisher & Paykel's operating leverage and changing clinical practices keep the medical-device maker among their top picks. The investment bank retains an outperform rating on the stock, citing a favorable medium-to-long term outlook.
Growth in CPAP Patients and Freight Costs
Analysts note that growth in the number of patients using CPAP machines supports the positive outlook. However, they warn that higher freight costs could weigh on fiscal 2027 margins. They currently expect revenue for the year to land in the middle of the company's guidance range.
Target Price and Stock Performance
Macquarie cut its target price on Fisher & Paykel's New Zealand-listed stock by 4.6% to NZ$43.70. Shares rose 1.6% to NZ$37.30 following the news.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.